174 related articles for article (PubMed ID: 16395307)
1. Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism.
Krystal JH; Madonick S; Perry E; Gueorguieva R; Brush L; Wray Y; Belger A; D'Souza DC
Neuropsychopharmacology; 2006 Aug; 31(8):1793-800. PubMed ID: 16395307
[TBL] [Abstract][Full Text] [Related]
2. Altered NMDA glutamate receptor antagonist response in individuals with a family vulnerability to alcoholism.
Petrakis IL; Limoncelli D; Gueorguieva R; Jatlow P; Boutros NN; Trevisan L; Gelernter J; Krystal JH
Am J Psychiatry; 2004 Oct; 161(10):1776-82. PubMed ID: 15465973
[TBL] [Abstract][Full Text] [Related]
3. Attenuation of ketamine effects by nimodipine pretreatment in recovering ethanol dependent men: psychopharmacologic implications of the interaction of NMDA and L-type calcium channel antagonists.
Krupitsky EM; Burakov AM; Romanova TN; Grinenko NI; Grinenko AY; Fletcher J; Petrakis IL; Krystal JH
Neuropsychopharmacology; 2001 Dec; 25(6):936-47. PubMed ID: 11750186
[TBL] [Abstract][Full Text] [Related]
4. Altered NMDA glutamate receptor antagonist response in recovering ethanol-dependent patients.
Krystal JH; Petrakis IL; Limoncelli D; Webb E; Gueorgueva R; D'Souza DC; Boutros NN; Trevisan L; Charney DS
Neuropsychopharmacology; 2003 Nov; 28(11):2020-8. PubMed ID: 12888778
[TBL] [Abstract][Full Text] [Related]
5. Dose-related ethanol-like effects of the NMDA antagonist, ketamine, in recently detoxified alcoholics.
Krystal JH; Petrakis IL; Webb E; Cooney NL; Karper LP; Namanworth S; Stetson P; Trevisan LA; Charney DS
Arch Gen Psychiatry; 1998 Apr; 55(4):354-60. PubMed ID: 9554431
[TBL] [Abstract][Full Text] [Related]
6. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects.
Krystal JH; Abi-Saab W; Perry E; D'Souza DC; Liu N; Gueorguieva R; McDougall L; Hunsberger T; Belger A; Levine L; Breier A
Psychopharmacology (Berl); 2005 Apr; 179(1):303-9. PubMed ID: 15309376
[TBL] [Abstract][Full Text] [Related]
7. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function.
Krystal JH; Perry EB; Gueorguieva R; Belger A; Madonick SH; Abi-Dargham A; Cooper TB; Macdougall L; Abi-Saab W; D'Souza DC
Arch Gen Psychiatry; 2005 Sep; 62(9):985-94. PubMed ID: 16143730
[TBL] [Abstract][Full Text] [Related]
8. Absence of significant interactive effects of high-dose D-cycloserine and ethanol in healthy human subjects: preliminary insights into ethanol actions at the glycine B site of NMDA glutamate receptors.
Trevisan L; Petrakis IL; Pittman B; Gueorguieva R; D'Souza DC; Perry E; Limoncelli D; Krystal JH
Alcohol Clin Exp Res; 2008 Jan; 32(1):36-42. PubMed ID: 18028532
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence.
Pettinati HM; Silverman BL; Battisti JJ; Forman R; Schweizer E; Gastfriend DR
Alcohol Clin Exp Res; 2011 Oct; 35(10):1804-11. PubMed ID: 21575016
[TBL] [Abstract][Full Text] [Related]
10. Lack of efficacy of dextromethorphan in managing alcohol withdrawal: a preliminary report of a randomized, double-blind, placebo-controlled trial.
Huang MC; Chen CH; Pan CH; Lin SK
J Clin Psychopharmacol; 2014 Feb; 34(1):149-52. PubMed ID: 24346753
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking.
Anton RF; Drobes DJ; Voronin K; Durazo-Avizu R; Moak D
Psychopharmacology (Berl); 2004 Apr; 173(1-2):32-40. PubMed ID: 14722705
[TBL] [Abstract][Full Text] [Related]
12. NMDA receptor antagonism and the ethanol intoxication signal: from alcoholism risk to pharmacotherapy.
Krystal JH; Petrakis IL; Krupitsky E; Schutz C; Trevisan L; D'Souza DC
Ann N Y Acad Sci; 2003 Nov; 1003():176-84. PubMed ID: 14684445
[TBL] [Abstract][Full Text] [Related]
13. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
14. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
15. Naltrexone-induced alterations in human ethanol intoxication.
Swift RM; Whelihan W; Kuznetsov O; Buongiorno G; Hsuing H
Am J Psychiatry; 1994 Oct; 151(10):1463-7. PubMed ID: 8092339
[TBL] [Abstract][Full Text] [Related]
16. Ethanol-like effects of thiopental and ketamine in healthy humans.
Dickerson D; Pittman B; Ralevski E; Perrino A; Limoncelli D; Edgecombe J; Acampora G; Krystal JH; Petrakis I
J Psychopharmacol; 2010 Feb; 24(2):203-11. PubMed ID: 19028835
[TBL] [Abstract][Full Text] [Related]
17. [Glutaminergic hypothesis of schizophrenia: clinical research studies with ketamine].
Mechri A; Saoud M; Khiari G; d'Amato T; Dalery J; Gaha L
Encephale; 2001; 27(1):53-9. PubMed ID: 11294039
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis.
O'Malley SS; Krishnan-Sarin S; Farren C; Sinha R; Kreek MJ
Psychopharmacology (Berl); 2002 Feb; 160(1):19-29. PubMed ID: 11862370
[TBL] [Abstract][Full Text] [Related]
19. 5-HT3 antagonist ICS 205-930 enhances naltrexone's effects on ethanol intake.
Mhatre M; Pruthi R; Hensley K; Holloway F
Eur J Pharmacol; 2004 May; 491(2-3):149-56. PubMed ID: 15140631
[TBL] [Abstract][Full Text] [Related]
20. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.
Malhotra AK; Pinals DA; Weingartner H; Sirocco K; Missar CD; Pickar D; Breier A
Neuropsychopharmacology; 1996 May; 14(5):301-7. PubMed ID: 8703299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
